903564-48-7 Usage
Uses
Used in Pharmaceutical Industry:
903564-48-7 is used as an antiretroviral medication for the treatment of HIV infection in adults and children over the age of six. It is effective in blocking the integration of HIV DNA into human cells, thereby preventing the virus from replicating and spreading within the body.
Used in Combination Therapy:
Dolutegravir is commonly used in combination with other antiretroviral drugs to suppress the virus and improve the health and quality of life of individuals living with HIV. This combination therapy enhances the overall effectiveness of the treatment and helps in managing the HIV infection more efficiently.
Used in HIV Prevention:
In addition to its therapeutic use, Dolutegravir is also being studied for its potential role in HIV prevention. It is being evaluated as a pre-exposure prophylaxis (PrEP) drug, which, when taken regularly, can significantly reduce the risk of acquiring HIV infection.
Used in Research and Development:
903564-48-7, as Dolutegravir, is also used in research and development for the discovery of new antiretroviral drugs and understanding the mechanisms of HIV integration and replication. This research can contribute to the development of more effective treatments and prevention strategies for HIV and other related diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 903564-48-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,0,3,5,6 and 4 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 903564-48:
(8*9)+(7*0)+(6*3)+(5*5)+(4*6)+(3*4)+(2*4)+(1*8)=167
167 % 10 = 7
So 903564-48-7 is a valid CAS Registry Number.
903564-48-7Relevant articles and documents
DUAL SRC/P38 KINASE INHIBITOR COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
-
, (2017/06/12)
Dual Src/p38 kinase inhibitor compounds and compositions comprising the same are disclosed. Methods of using the compounds in the treatment of hyperproliferative disease such as cancer are also disclosed.
COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS
-
Page/Page column 24-26, (2008/06/13)
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, FGFR3, PDGFRβ and b-Raf kinases.
